Comparison of topical brinzolamide 1% and dorzolamide 2% eye drops given twice daily in addition to timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension

American Journal of Ophthalmology

Volumn 132, Issue 2, 2001, Pages 235-243

  Michaud, Jean Eric ^a,b   Friren, Béatrice ^a  

^a ALCON RESEARCH LTD   (United States)

^b Alcon Laboratories Ltd UK   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BRINZOLAMIDE; DORZOLAMIDE; EYE DROPS; TIMOLOL;

ADULT; ARTICLE; CIRCADIAN RHYTHM; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERANCE; EYE DISEASE; FEMALE; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; MAJOR CLINICAL STUDY; MALE; OPEN ANGLE GLAUCOMA; PRIORITY JOURNAL;

ADMINISTRATION, TOPICAL; ADRENERGIC BETA-ANTAGONISTS; AGED; CARBONIC ANHYDRASE INHIBITORS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; GLAUCOMA, OPEN-ANGLE; HUMANS; INTRAOCULAR PRESSURE; MALE; MIDDLE AGED; OCULAR HYPERTENSION; OPHTHALMIC SOLUTIONS; SAFETY; SULFONAMIDES; THIAZINES; THIOPHENES; TIMOLOL; TREATMENT OUTCOME;

EID: 0034907128     PISSN: 00029394     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9394(01)00974-6     Document Type: Article

References (18)

1. Wang RF, Serie JB, Podos SM, Sugrue MF. The effect of MK-927, a topical carbonic anhydrase inhibitor, on IOP in glaucomatous monkeys. Curr Eye Res 1989;9:163-168.
2. Serle JB, Lustgarten JS, Lippa FA, Camras CB, Panebianco DL, Podos SM. MK-927, a topical carbonic anhydrase inhibitor. Dose response and reproducibility. Arch Ophthalmol 1990;108:838-841.
3. Lippa EA, Schuman JS, Higginbotham EJ, et al. MK-507 versus sezolamide: comparative efficacy of two topically active carbonic anhydrase inhibitors. Ophthalmology 1991; 98:308-312.
4. Rusk C, Sharpe E, Laurence J, Polis A, Adamsons I, Dorzolamide Comparison Study Group. Comparison of the efficacy and safety of 2% dorzolamide and 0.5% betaxolol in the treatment of elevated intraocular pressure. Clin Ther 1998;20:454-466.
5. Strahlman E, Tipping R, Vogel R. A double-masked, randomized 1-year study comparing dorzolamide (Trusopt), timolol, and betaxolol. International Dorzolamide Study Group. Arch Ophthalmol 1995;! 13:1009-1016.
6. Silver LH. Clinical efficacy and safety of brinzolamide (Azopt), a new topical carbonic anhydrase inhibitor for primary open-angle glaucoma and ocular hypertension. Brinzolamide Primary Therapy Study Group. Am J Ophthalmol 1998; 126:400-408.
7. Shin D, the Brinzolamide Adjunctive Therapy Study Group. Adjunctive therapy with brinzolamide 1% ophthalmic suspension (AZOPT) in patients with open-angle glaucoma or ocular hypertension maintained on timolol therapy. Surv Ophthalmol 2000;44(4 suppl 2):163-168.
8. Adamsons IA, Polis A, Ostrov CS, Boyle JE, Dorzolamide Safety Study Group. Two-year safety study of dorzolamide as monotherapy and with timolol and pilocarpine. J Glaucoma 1998;7:395-401.
9. March WF, Ochsner KI, The Brinzolamide Long-Term Therapy Study Group. The long-term safety and efficacy of brinzolamide 1.0% (AZOPT) in patients with primary open-angle glaucoma or ocular hypertension. Am J Ophthalmol 2000;129:136-143.
10. Strahlman ER, Vogel R, Tipping R, Clineschmidt CM, The Dorzolamide Additivity Study Group. The use of dorzolamide and pilocarpine as adjunctive therapy to timolol in patients with elevated intraocular pressure. Ophthalmology 1996;103:1283-1293.
11. Garcia Sanchez J, Spanish Latanoprost Study Group. Efficacy and side effects of latanoprost monotherapy compared to adding dorzolamide to timolol in patients with glaucoma and ocular hypertension - a three-month randomised study. Eur J Ophthalmol 2000; 10:198-204.
12. Phelps CD, Phelps GK. Measurement of intraocular pressure: a study of its reproducibility. Graefes Arch Clin Exp Ophthalmol 1976;198:39-43.
13. Motoklo MA, Feldman F, Hyde M, Hudy D. Sources of variability in the results of applanation tonometry. Can J Ophthalmol 1982;17:93-95.
14. Kass MA. Standardizing the measurement of intraocular pressure for clinical research. Guidelines from the Eye Care Technology Forum. Ophthalmology 1996;103:183-185.
15. Kitazawa Y, Hoie T. Diurnal variation of intraocular pressure in primary open-angle glaucoma. Am J Ophthalmol 1975;79:557-566.
16. Hutzelmann JE, Polis AB, Michael AJ, Adamsons IA. The Oral to Topical CAI Study Group. A comparison of the efficacy and tolerability of dorzolamide and acetazolamide as adjunctive therapy to timolol. Acta Ophthalmol Scand 1998;76:717-722.
17. Silver LH, the Brinzolamide Comfort Study Group. Ocular comfort of brinzolamide 1.0% ophthalmic suspension compared with dorzolamide 2.0% ophthalmic solution. Results from two multicenter comfort studies. Surv Ophthalmol 2000;44(4 suppl 2):141-145.
18. Barnebey H, Kwok SY. Patient's acceptance of a switch from dorzolamide to brinzolamide for the treatment of glaucoma in a clinical practice setting. Clin Ther 2000;22:1204-1212.